Related Experiment Videos
Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue
Abstract:
para-Methoxyamphetamine (PMA), a known hallucinogen, is the most potent compound among methoxyamphetamines in disrupting behavior in rats. PMA, unlike d-amphetamine (A), did not induce stereotyped behavior and was less effective than A in stimulation of locomotor d-amphetamine-like effects, but ortho-methoxyamphetamine (OMA) was devoid of any locomotor stimulation. To investigate the reasons for the different behavioral effects caused by PMA, meta-methoxyamphetamine (MMA), OMA and A, a comparison was made among these drugs on the release and uptake of 3H-5-hydroxytryptamine (3H-5-HT), 3H-norepinephrine (3H-NE) and 3H-dopamine (3H-DA) in tissue slices of cerebral cortex and corpus striatum of rat brain. The potencies for the increased release of 3H-5-HT were found to be PMA greater than MMA greater than or equal to A greater than OMA in cerebral cortex of 3H-NE in cortex, A greater than or equal to PMA = MMA greater than OMA, and of 3H-DA in corpus striatum, A greater than MMA greater than PMA greater than or equal to OMA. The potencies for inhibiting the uptake of 3H-5-HT in cerebral cortex and corpus striatum were found to be PMA greater than MMA greater than A greater than OMA and of 3H-NE in cortex A greater than PMA greater than or equal to MMA greater than OMA, and 3H-DA in corpus striatum A greater than MMA greater than PMA greater than OMA. d-PMA is equipotent to l-PMA in increasing the release of 3H-5-HT but is more potent than l-PMA in blocking the uptake of 3H-5-HT. The high potency of PMA on increasing the release and inhibiting the uptake of 5-HT suggests than 5-HT may be involved in the production of hallucinogenic effects of PMA.
Insights
Para-Methoxyamphetamine (PMA) is a potent hallucinogen that affects serotonin (5-HT) release and uptake in the brain. Its high activity on 5-HT pathways suggests a role in producing hallucinogenic effects.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Methoxyamphetamines, including para-Methoxyamphetamine (PMA), exhibit varied behavioral effects in rats.
- PMA is a potent hallucinogen, distinct from d-amphetamine in its behavioral profile, notably lacking stereotyped behavior and potent locomotor stimulation.
Purpose of the Study:
- To investigate the neurochemical underpinnings of differential behavioral effects among PMA, meta-methoxyamphetamine (MMA), ortho-methoxyamphetamine (OMA), and d-amphetamine (A).
- To compare the effects of these compounds on the release and reuptake of key neurotransmitters: serotonin (5-HT), norepinephrine (NE), and dopamine (DA) in rat brain tissue.
Main Methods:
- In vitro assessment of neurotransmitter release and uptake inhibition using radiolabeled tracers (3H-5-HT, 3H-NE, 3H-DA) in rat cerebral cortex and corpus striatum slices.
- Comparative analysis of drug potencies across different neurotransmitter systems and brain regions.
Main Results:
- PMA demonstrated the highest potency in increasing 3H-5-HT release and inhibiting 3H-5-HT uptake in both cerebral cortex and corpus striatum.
- The potencies for 3H-5-HT release followed the order: PMA > MMA ≥ A > OMA.
- The potencies for 3H-5-HT uptake inhibition were: PMA > MMA > A > OMA.
- Stereoisomers of PMA showed equipotency in 3H-5-HT release but differential potency in 3H-5-HT uptake inhibition (d-PMA > l-PMA).
Conclusions:
- The potent effects of PMA on serotonin (5-HT) release and reuptake strongly suggest that 5-HT plays a crucial role in mediating PMA's hallucinogenic properties.
- Differential interactions with monoamine systems explain the distinct behavioral profiles observed for PMA and related methoxyamphetamines.